CJC-1295 isn't found on pharmacy shelves in Borre or most other cities — it's a research compound distributed through a dedicated online market. This online-only market structure is actually an advantage for quality — top vendors differentiate through analytical documentation in ways brick-and-mortar outlets simply cannot. What reliably differentiates top CJC-1295 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for safety screening. The sections below cover what Borre researchers need to know about finding, evaluating, and storing CJC-1295 for legitimate research applications.
CJC-1295: What the Research Shows
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Borre studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Where to Buy CJC-1295 — A Researcher's Guide
Evaluating CJC-1295 vendors begins with the COA: access the batch-specific certificate prior to buying, not after. The HPLC chromatogram is the most important document in the COA: it should show a clear dominant peak representing CJC-1295, with minimal secondary peaks representing impurities — purity should be stated as ≥98%. Community reputation in research forums is a useful additional signal to COA verification — vendors with multi-year positive track records have built their reputation on real product performance. For Borre researchers making a first CJC-1295 purchase: apply these quality criteria before ordering, order conservatively at first, and verify batch traceability on arrival before use.
Order CJC-1295 — ships to Borre
COA-verified · International tracking · Research grade
CJC-1295 is sold for research purposes only and is not approved for human use by the FDA or comparable health authorities — all information here is for educational purposes only. Proper handling of CJC-1295 requires careful sterile procedure — swabbed septum with alcohol prep pad, new needle for each draw, clean preparation area — and cold chain maintenance from receipt through use. Bacterial endotoxin contamination is the most serious safety risk unique to this class of compound — verify endotoxin testing is present in the lot-matched certificate before any injectable research application. PubMed provide the most complete literature coverage for CJC-1295 research; prioritise peer-reviewed studies with characterised source material over conference abstracts or single case observations.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
